MCID: BNS003
MIFTS: 41

Binswanger's Disease

Categories: Rare diseases

Aliases & Classifications for Binswanger's Disease

MalaCards integrated aliases for Binswanger's Disease:

Name: Binswanger's Disease 20 53
Multi-Infarct Dementia 20 70
Dementia Multi-Infarct 20 54
Binswanger Disease 54 70

Classifications:



External Ids:

UMLS 70 C0011263 C0270786

Summaries for Binswanger's Disease

NINDS : 53 Binswanger's disease (BD), also called subcortical vascular dementia, is a type of dementia caused by widespread, microscopic areas of damage to the deep layers of white matter in the brain. The damage is the result of the thickening and narrowing (atherosclerosis) of arteries that feed the subcortical areas of the brain. Atherosclerosis (commonly known as "hardening of the arteries") is a systemic process that affects blood vessels throughout the body. It begins late in the fourth decade of life and increases in severity with age. As the arteries become more and more narrowed, the blood supplied by those arteries decreases and brain tissue dies. A characteristic pattern of BD-damaged brain tissue can be seen with modern brain imaging techniques such as CT scans or magnetic resonance imaging (MRI). The symptoms associated with BD are related to the disruption of subcortical neural circuits that control what neuroscientists callexecutive cognitive functioning: short-term memory, organization, mood, the regulation of attention, the ability to act or make decisions, and appropriate behavior. The most characteristic feature of BD is psychomotor slowness - an increase in the length of time it takes, for example, for the fingers to turn the thought of a letter into the shape of a letter on a piece of paper. Other symptoms include forgetfulness (but not as severe as the forgetfulness of Alzheimer's disease), changes in speech, an unsteady gait, clumsiness or frequent falls, changes in personality or mood (most likely in the form of apathy, irritability, and depression), and urinary symptoms that aren't caused by urological disease. Brain imaging, which reveals the characteristic brain lesions of BD, is essential for a positive diagnosis.

MalaCards based summary : Binswanger's Disease, also known as multi-infarct dementia, is related to subcortical arteriosclerotic encephalopathy and aphasia. An important gene associated with Binswanger's Disease is SYP (Synaptophysin), and among its related pathways/superpathways are Neuroscience and Alzheimers Disease. The drugs Cilostazol and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include brain, pituitary and breast, and related phenotypes are behavior/neurological and growth/size/body region

GARD : 20 Binswanger's disease is a type of dementia caused by widespread, microscopic areas of damage to the deep layers of white matter in the brain. Most affected people experience progressive memory loss and deterioration of intellectual abilities (dementia); urinary urgency or incontinence; and an abnormally slow, unsteady gait (style of walking). While there is no cure, the progression of Binswanger's disease can be slowed with healthy lifestyle choices. Treatment is based on the signs and symptoms present in each person.

Related Diseases for Binswanger's Disease

Diseases related to Binswanger's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 336)
# Related Disease Score Top Affiliating Genes
1 subcortical arteriosclerotic encephalopathy 32.2 VIP GFAP
2 aphasia 30.1 MAPT APP APOE
3 alexia 30.1 MAPT APOE
4 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 30.1 NOTCH3 APP APOE
5 visual agnosia 29.9 MAPT APOE
6 nominal aphasia 29.9 MAPT APOE ACHE
7 ideomotor apraxia 29.9 MAPT APOE
8 vascular dementia 29.8 NOTCH3 MAPT APP APOE ACHE
9 alzheimer disease 7 29.8 MAPT APOE
10 dyscalculia 29.8 MAPT APOE
11 hydrocephalus 29.7 SYP MAPT GFAP APP APOE
12 mild cognitive impairment 29.6 MAPT APP APOE
13 transient cerebral ischemia 29.6 NOTCH3 MAPT ACHE
14 arteriolosclerosis 29.6 NOTCH3 MAPT APP APOE
15 agraphia 29.6 MAPT APOE ACHE
16 cerebral amyloid angiopathy, cst3-related 29.5 MAPT APP APOE
17 amnestic disorder 29.4 MAPT APP APOE ACHE
18 sleep disorder 29.4 MAPT CRH APOE
19 creutzfeldt-jakob disease 29.1 MAPT GFAP APP APOE
20 normal pressure hydrocephalus 29.1 VIP SST MAPT GFAP APP APOE
21 huntington disease 29.1 SST MAPT APP ACHE
22 central nervous system disease 28.9 PLP1 MAPT GFAP APP APOE
23 cerebrovascular disease 28.8 RECK NOTCH3 MAPT APP APOE ACHE
24 supranuclear palsy, progressive, 1 28.8 MAPT GFAP APP APOE ACHE
25 nervous system disease 28.8 MAPT GFAP APP APOE ACHE
26 dementia 28.6 SYP NOTCH3 MAPT GFAP APP APOE
27 alzheimer disease 28.3 SYP SST MAPT GFAP APP APOE
28 microangiopathy and leukoencephalopathy, pontine, autosomal dominant 11.3
29 dementia - subcortical 11.1
30 encephalopathy 10.6
31 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2 10.5
32 glomangiomyoma 10.4 SYP ACTC1
33 glycogen-rich clear cell breast carcinoma 10.4 SYP ACTC1
34 primary hepatic neuroendocrine carcinoma 10.4 SYP CHGA
35 esophageal neuroendocrine tumor 10.4 SYP CHGA
36 auditory system benign neoplasm 10.4 SYP CHGA
37 acinar cell cystadenocarcinoma 10.4 SYP CHGA
38 vulvar eccrine porocarcinoma 10.4 SYP CHGA
39 pancreatic serous cystadenocarcinoma 10.4 SYP CHGA
40 cauda equina neoplasm 10.4 SYP CHGA
41 appendix carcinoid tumor 10.4 SYP CHGA
42 vaginal tubulovillous adenoma 10.4 SYP CHGA
43 mixed ductal-endocrine carcinoma 10.4 SYP CHGA
44 laryngeal small cell carcinoma 10.4 SYP CHGA
45 gallbladder small cell carcinoma 10.4 SYP CHGA
46 ureter small cell carcinoma 10.4 SYP CHGA
47 papillary thymic adenocarcinoma 10.4 SYP CHGA
48 middle ear adenoma 10.4 SYP CHGA
49 urinary bladder small cell neuroendocrine carcinoma 10.4 SYP CHGA
50 gastric small cell carcinoma 10.4 SYP CHGA

Graphical network of the top 20 diseases related to Binswanger's Disease:



Diseases related to Binswanger's Disease

Symptoms & Phenotypes for Binswanger's Disease

MGI Mouse Phenotypes related to Binswanger's Disease:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.24 ACHE APOE APP CRH GFAP MAPT
2 growth/size/body region MP:0005378 10.21 ACHE ACTC1 APOE APP CHGA CRH
3 cardiovascular system MP:0005385 10.18 ACHE ACTC1 APOE APP CHGA GFAP
4 homeostasis/metabolism MP:0005376 10.18 ACHE ACTC1 APOE APP CHGA CRH
5 cellular MP:0005384 10.11 ACTC1 APOE APP CRH GFAP MAPT
6 mortality/aging MP:0010768 10.1 ACHE ACTC1 APOE APP CHGA GFAP
7 immune system MP:0005387 10.02 APOE APP CRH GFAP MAPT NOTCH3
8 nervous system MP:0003631 9.97 ACHE ACTC1 APOE APP CHGA CRH
9 muscle MP:0005369 9.91 ACHE ACTC1 APOE APP CHGA GFAP
10 no phenotypic analysis MP:0003012 9.5 ACHE APOE APP CHGA CRH MAPT
11 normal MP:0002873 9.28 ACTC1 APP CRH GFAP MAPT NOTCH3

Drugs & Therapeutics for Binswanger's Disease

Drugs for Binswanger's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cilostazol Approved, Investigational Phase 1, Phase 2 73963-72-1 2754
2
Tocopherol Approved, Investigational Phase 2 1406-66-2
3
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2 59-02-9 14985
4
Dabigatran Investigational Phase 2 211914-51-1
5 Tocotrienol Investigational Phase 2 6829-55-6
6 Anticoagulants Phase 2
7 Serine Proteinase Inhibitors Phase 2
8 Antithrombin III Phase 2
9 Antithrombins Phase 2
10 HIV Protease Inhibitors Phase 2
11
protease inhibitors Phase 2
12 Fibrinolytic Agents Phase 1, Phase 2
13 Respiratory System Agents Phase 1, Phase 2
14 Vasodilator Agents Phase 1, Phase 2
15 Anti-Asthmatic Agents Phase 1, Phase 2
16 Phosphodiesterase Inhibitors Phase 1, Phase 2
17 Neuroprotective Agents Phase 1, Phase 2
18 Phosphodiesterase 3 Inhibitors Phase 1, Phase 2
19 Protective Agents Phase 1, Phase 2
20 Platelet Aggregation Inhibitors Phase 1, Phase 2
21 Bronchodilator Agents Phase 1, Phase 2
22 Micronutrients Phase 2
23 Trace Elements Phase 2
24 Nutrients Phase 2
25 Antioxidants Phase 2
26 Vitamins Phase 2
27 Soy Bean Phase 2
28 Tocotrienols Phase 2
29 Tocovid Phase 2
30 Tocopherols Phase 2
31
Serine Investigational, Nutraceutical Phase 2 56-45-1 5951

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 Phase II, Randomized, Crossover, Single Blind, Safety Trial of DABIGATRAN Versus ASA for Preventing Ischaemic Brain Lesions in Patients Affected by CADASIL Unknown status NCT01361763 Phase 2 Dabigatran;Antiplatelets
2 Retinal Vasoreactivity is a Marker for Cerebral Small Vessel Disease Progression Recruiting NCT04753970 Phase 1, Phase 2 Cilostazol
3 A Randomized Placebo-controlled Double-blind Pilot / Phase II Study to Assess the Efficacy and Safety of HOV-12020 in Patients With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Recruiting NCT04658823 Phase 2 HOV-12020 (Palm tocotrienols complex);Placebo
4 A Phase II Double-Blinded Placebo Controlled Individual Subject Stepped Wedge Clinical Trial Evaluating the Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL Not yet recruiting NCT04334408 Phase 2 Fremanezumab;Placebo
5 Etude Comparative en Imagerie Par résonnance magnétique et Par Enregistrement électroencéphalographique du Couplage Neurovasculaire Dans l'Angiopathie Cadasil Unknown status NCT02071784
6 Obtention d'un modèle Cellulaire de la Maladie CADASIL à Partir de Fibroblastes cutanés de Patients Unknown status NCT02032225
7 Natural History of CADASIL: Migraine, Diagnosis and Misdiagnosis Completed NCT01114815
8 Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study Recruiting NCT03724136
9 Evaluating the Effectiveness of an Online Small-Group Self-Management Workshop for Rural Caregivers of Individuals With Alzheimer's Disease and Related Dementias Recruiting NCT04428112
10 Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy Registry Study Recruiting NCT04310098
11 Développement de Nouveaux Biomarqueurs en Imagerie Par résonance magnétique Pour Les études Longitudinales Dans l'Angiopathie CADASIL Recruiting NCT04036084
12 CADASIL Disease Discovery Active, not recruiting NCT02821780
13 A Training and Fidelity Model to Move and Scale Evidence-based Dementia Care and Caregiver Support Programs Into Practice: The Case for COPE in PACE Service Settings Not yet recruiting NCT04165213
14 Virtual CST - A Collaborative Proof of Concept Study With FaceCog HK in Response to the Covid-19 Pandemic Not yet recruiting NCT04828434

Search NIH Clinical Center for Binswanger's Disease

Genetic Tests for Binswanger's Disease

Anatomical Context for Binswanger's Disease

MalaCards organs/tissues related to Binswanger's Disease:

40
Brain, Pituitary, Breast, Appendix, Cortex, Cerebellum, Lung

Publications for Binswanger's Disease

Articles related to Binswanger's Disease:

(show top 50) (show all 1168)
# Title Authors PMID Year
1
Hereditary multi-infarct dementia of the Swedish type is a novel disorder different from NOTCH3 causing CADASIL. 61 54
17235124 2007
2
Metallothionein I-II immunocytochemical reactivity in Binswanger's encephalopathy. 61 54
12515897 2002
3
Schizophrenia in a patient with cerebral autosomally dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL disease). 54 61
11827605 2001
4
An CSF anamalous molecular form of acetylcholinesterase in demented and non-demented subjects. 54 61
9351648 1997
5
Alterations in glia and axons in the brains of Binswanger's disease patients. 61 54
9227695 1997
6
Apolipoprotein E genotypes and serum lipid levels in Alzheimer's disease and multi-infarct dementia. 61 54
9152721 1997
7
Apolipoprotein E genotype and Alzheimer's disease in Hong Kong elderly Chinese. 54 61
8559364 1996
8
Lower cognitive performance in normal older adult male twins carrying the apolipoprotein E epsilon 4 allele. 61 54
7986172 1994
9
Synaptophysin immunoreactivity of the cortical neuropil in vascular dementia of Binswanger type compared with the dementia of Alzheimer type and nondemented controls. 61 54
8038870 1994
10
Effect of CDP-choline on cognition and immune function in Alzheimer's disease and multi-infarct dementia. 61 54
8239305 1993
11
Cerebrospinal fluid corticotropin-releasing hormone and ACTH, and peripherally circulating choline-containing phospholipid in senile dementia. 61 54
8394971 1993
12
Interleukin-1 in Alzheimer's disease and multi-infarct dementia: neuropsychological correlations. 61 54
1770834 1991
13
Quantitative changes in the amyloid beta A4 precursor protein in Alzheimer cerebrospinal fluid. 54 61
1677459 1991
14
Cerebrospinal fluid and plasma corticotropin-releasing hormone in senile dementia. 54 61
1645837 1991
15
Neuropeptides in cerebrospinal fluid in normal-pressure hydrocephalus and dementia. 54 61
1675171 1991
16
Episode of mixed mood with psychotic features secondary to Binswanger disease: a case report with a literature review. 61
33664028 2021
17
A Deep Ensemble Predictor for Identifying Anti-Hypertensive Peptides Using Pre-trained Protein Embedding. 61
33760739 2021
18
Telemedicine and the rural dementia population: A systematic review. 61
33308615 2021
19
Rare case of Marchiafava-Bignami disease due to thiamine deficiency and malnutrition. 61
33303506 2020
20
Cerebral Small Vessel Disease. 61
33419271 2020
21
Binswanger's disease: Case presentation and differential diagnosis. 61
33363950 2020
22
CGA ameliorates cognitive decline by regulating the PI3K/AKT signaling pathway and neurotransmitter systems in rats with multi-infarct dementia. 61
32963600 2020
23
Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. 61
32001681 2020
24
In search of multimodal brain alterations in Alzheimer's and Binswanger's disease. 61
31351845 2020
25
Intracerebral Transcatheter Laser Photobiomodulation Therapy in the Treatment of Binswanger's Disease and Vascular Parkinsonism: Research and Clinical Experience. 61
31390288 2019
26
Neuro-regeneration Therapeutic for Alzheimer's Dementia: Perspectives on Neurotrophic Activity. 61
31402121 2019
27
Biomarkers identify the Binswanger type of vascular cognitive impairment. 61
29513153 2019
28
X-Linked Lymphoproliferative Syndrome Presenting as Adult-Onset Multi-Infarct Dementia. 61
30990878 2019
29
A case of hypertension with dementia: Common but underdiagnosed. 61
30090792 2018
30
Binswanger's disease: biomarkers in the inflammatory form of vascular cognitive impairment and dementia. 61
28902409 2018
31
Driving and Patients With Dementia. 61
29900187 2018
32
Multi-infarct dementia of Swedish type is caused by a 3'UTR mutation of COL4A1. 61
28369186 2017
33
Extracellular matrix inflammation in vascular cognitive impairment and dementia. 61
28265034 2017
34
Multi-Infarct Dementia: A Historical Perspective. 61
28626470 2017
35
[Degenerative cerebellar diseases and differential diagnoses]. 61
27783098 2016
36
The pathophysiological role of astrocytic endothelin-1. 61
27132521 2016
37
Elevation of the ACTH/cortisol ratio in female opioid dependent patients: A biomarker of aging and correlate of metabolic and immune activation. 61
27857051 2016
38
Quantitative EEG Neurometric Analysis-Guided Neurofeedback Treatment in Dementia: 20 Cases. How Neurometric Analysis Is Important for the Treatment of Dementia and as a Biomarker? 61
26099949 2016
39
Animal Models of Vascular Cognitive Impairment and Dementia (VCID). 61
26988696 2016
40
Matrix Metalloproteinase-Mediated Neuroinflammation in Vascular Cognitive Impairment of the Binswanger Type. 61
26993507 2016
41
[Effects of Tongluo Xingnao effervescent tablets on blood rheology, iNOS, VEGF and LDH-5 in MID rats]. 61
28875680 2016
42
Consensus statement for diagnosis of subcortical small vessel disease. 61
26198175 2016
43
Multi-infarct dementia and Alzheimer disease, contribution of cerebral circulation ultrasonography to pathogenesis and differential diagnosis. Value of microembolisation. 61
27179577 2016
44
The risk of overweight/obesity in mid-life and late life for the development of dementia: a systematic review and meta-analysis of longitudinal studies. 61
26764391 2016
45
Serum neuron specific enolase - a novel indicator for neuropsychiatric systemic lupus erythematosus? 61
26124236 2015
46
Ekbom syndrome occurring with multi infarct dementia. 61
26023627 2015
47
Progressive cognitive deficits in a mouse model of recurrent photothrombotic stroke. 61
25744521 2015
48
Cerebral small vessel disease and Alzheimer's disease. 61
26604717 2015
49
MRI features of Binswanger's disease predict prognosis and associated pathology. 61
25493272 2014
50
Binswanger's disease: toward a diagnosis agreement and therapeutic approach. 61
25201523 2014

Variations for Binswanger's Disease

Expression for Binswanger's Disease

Search GEO for disease gene expression data for Binswanger's Disease.

Pathways for Binswanger's Disease

Pathways related to Binswanger's Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.7 VIP SYP NOTCH3 MAPT GFAP APP
2 11.51 MAPT APP APOE
3 11.44 MAPT APP APOE
4 10.79 MAPT APP APOE

GO Terms for Binswanger's Disease

Cellular components related to Binswanger's Disease according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.95 SST CRH CHGA APP APOE ACTC1
2 neuron projection GO:0043005 9.8 VIP SYP MAPT APP
3 neuronal cell body GO:0043025 9.78 SST MAPT CRH APOE
4 perikaryon GO:0043204 9.69 VIP CRH APP
5 cell body GO:0044297 9.5 MAPT GFAP ACTC1
6 synaptic cleft GO:0043083 9.46 APOE ACHE
7 astrocyte projection GO:0097449 9.43 GFAP APP
8 neuromuscular junction GO:0031594 9.43 SYP APP ACHE
9 synapse GO:0045202 9.43 SYP SST PLP1 CRH APP ACHE
10 glial cell projection GO:0097386 9.37 MAPT GFAP
11 extracellular region GO:0005576 9.32 VIP SST RECK NOTCH3 MAPT CRH
12 main axon GO:0044304 9.16 MAPT APP

Biological processes related to Binswanger's Disease according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.67 MAPT CRH APP APOE
2 regulation of protein complex assembly GO:0043254 9.55 GFAP APOE
3 response to lead ion GO:0010288 9.54 MAPT APP
4 regulation of long-term neuronal synaptic plasticity GO:0048169 9.52 SYP APP
5 regulation of neuronal synaptic plasticity GO:0048168 9.51 SYP APOE
6 astrocyte development GO:0014002 9.49 PLP1 GFAP
7 axon development GO:0061564 9.48 PLP1 MAPT
8 astrocyte activation GO:0048143 9.46 MAPT APP
9 negative regulation of long-term synaptic potentiation GO:1900272 9.43 APP APOE
10 amyloid fibril formation GO:1990000 9.4 MAPT APP
11 amyloid precursor protein metabolic process GO:0042982 9.32 APOE ACHE
12 positive regulation of amyloid fibril formation GO:1905908 9.26 APP APOE
13 neuron projection development GO:0031175 9.26 PLP1 MAPT APP APOE
14 hormone-mediated apoptotic signaling pathway GO:0008628 9.16 SST CRH
15 learning or memory GO:0007611 8.92 VIP MAPT CRH APP

Molecular functions related to Binswanger's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.33 VIP SST CRH
2 identical protein binding GO:0042802 9.23 SYP PLP1 NOTCH3 MAPT GFAP APP
3 lipoprotein particle binding GO:0071813 8.96 MAPT APOE

Sources for Binswanger's Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....